Mounjaro and GLP-1: The Drug Class, Mechanism, and Genetics

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

The phrase “mounjaro glp 1” is really a class-level question: where does Mounjaro sit among GLP-1 medications, and how does the underlying hormone work? This article covers GLP-1 as a hormone, the mechanism of receptor agonists, which drugs belong to the class, their FDA-approved uses, the shared safety profile, and the genetics upstream of all of it.

GLP-1, the hormone

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released by enteroendocrine L-cells in the small intestine after eating. It triggers glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 lasts only minutes because the enzyme DPP-4 degrades it almost immediately.

How receptor agonists extend it

GLP-1 receptor agonists are peptides — and, in emerging cases, small molecules — that bind the GLP-1 receptor while resisting DPP-4 breakdown, stretching the half-life from minutes to hours or days. They reproduce native GLP-1’s effects at a pharmacological level. GIP/GLP-1 dual agonists such as tirzepatide additionally engage the GIP receptor, layering in a second incretin mechanism.

Which drugs are in the class

FDA-approved GLP-1 receptor agonists as of April 2026 include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide (historically; discontinued in the U.S.), and semaglutide (Ozempic, Wegovy, Rybelsus). Tirzepatide (Mounjaro, Zepbound) is the GIP/GLP-1 dual agonist. The investigational triple agonist retatrutide (GLP-1/GIP/glucagon) has Phase 3 data but is not FDA-approved, and emerging oral non-peptide agonists such as orforglipron remain in late-stage development.

FDA-approved uses

Indications vary by compound and product: type 2 diabetes (most products), chronic weight management (Wegovy, Saxenda, Zepbound), cardiovascular risk reduction in type 2 diabetes (Ozempic, Trulicity, Victoza, Rybelsus), and obstructive sleep apnea in adults with obesity (Zepbound, December 2024). Certain products also carry pediatric indications. FDA labeling governs what is prescribed for which use.

The safety profile the class shares

Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. The most common side effects are gastrointestinal and usually peak during dose escalation; serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

The genetics beneath the class

Underneath the entire class sits your own biology. Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1, appetite-regulation, and energy-balance biology. They are pathway-level markers — they do not predict response to any one compound, but they describe the terrain every GLP-1 drug operates on. See the PlexusDx primer What Is GLP-1 for the pathway explanation.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, MC4R, and TCF7L2 variants that shape your baseline biology. That is test before you invest.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is a GLP-1 receptor agonist?

It is a peptide, or in emerging cases a small molecule, that binds the GLP-1 receptor and resists rapid DPP-4 degradation. It stimulates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety. FDA-approved examples include semaglutide, tirzepatide (a GIP/GLP-1 dual agonist), liraglutide, and dulaglutide.

How do dual agonists differ from single GLP-1 agonists?

GLP-1 receptor agonists engage only the GLP-1 receptor, while GIP/GLP-1 dual agonists such as tirzepatide add the GIP receptor for a second incretin mechanism. Clinical trial programs (SURPASS, SURMOUNT) suggest the dual-receptor approach may produce larger mean effects on weight and glycemic control in some trial populations.

Who should not use a GLP-1 receptor agonist?

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated per every FDA label in the class. Those with severe gastrointestinal disease or a history of pancreatitis need careful clinical review. Discuss your full history with a provider first.

Does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

It does not predict response to any specific compound in the class. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across every GLP-1 receptor agonist and GIP/GLP-1 dual agonist.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education